APLLTD

Alembic Pharmaceuticals Share Price

₹1,049.40 +13.55 (1.31%)

28 Dec, 2024 02:27

SIP TrendupStart SIP in APLLTD

Start SIP

Performance

  • Low
  • ₹1,033
  • High
  • ₹1,055
  • 52 Week Low
  • ₹747
  • 52 Week High
  • ₹1,304
  • Open Price₹1,034
  • Previous Close₹1,036
  • Volume167,630

Investment Returns

  • Over 1 Month -4.49%
  • Over 3 Month -12.24%
  • Over 6 Month + 16.58%
  • Over 1 Year + 35.01%
SIP Lightning

Smart Investing Starts Here Start SIP with Alembic Pharmaceuticals for Steady Growth!

Invest Now

Alembic Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 31.9
  • PEG Ratio
  • 1.5
  • Market Cap Cr
  • 20,627
  • P/B Ratio
  • 4.3
  • Average True Range
  • 32.03
  • EPS
  • 32.4
  • Dividend Yield
  • 1
  • MACD Signal
  • -10.35
  • RSI
  • 44.99
  • MFI
  • 55.88

Alembic Pharmaceuticals Financials

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,049.40
+ 13.55 (1.31%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹1,060.20
  • 50 Day
  • ₹1,080.41
  • 100 Day
  • ₹1,082.70
  • 200 Day
  • ₹1,038.64

Resistance and Support

1045.58 Pivot Speed
  • R3 1,080.87
  • R2 1,067.83
  • R1 1,058.62
  • S1 1,036.37
  • S2 1,023.33
  • S3 1,014.12

What's your outlook on Alembic Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Alembic Pharmaceuticals Limited, manufactures and markets India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs). With a strong R&D focus, Alembic derives over $600 million in revenue, with significant contributions from India and the US markets.

Alembic Pharmaceuticals has an operating revenue of Rs. 6,357.26 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 10% is healthy, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 42 which is a POOR score indicating inconsistency in earnings, a RS Rating of 49 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alembic Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-07 Quarterly Results
2024-08-08 Quarterly Results
2024-05-09 Audited Results & Final Dividend
2024-02-05 Quarterly Results
2023-11-07 Quarterly Results
Date Purpose Remarks
2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)

Alembic Pharmaceuticals F&O

Alembic Pharmaceuticals Shareholding Pattern

69.61%
8.9%
6.71%
3.94%
0.03%
7.35%
3.46%

About Alembic Pharmaceuticals

  • NSE Symbol
  • APLLTD
  • BSE Symbol
  • 533573
  • Managing Director
  • Mr. Pranav Amin
  • ISIN
  • INE901L01018

Similar Stocks to Alembic Pharmaceuticals

Alembic Pharmaceuticals FAQs

Alembic Pharmaceuticals share price is ₹1,049 As on 28 December, 2024 | 02:13

The Market Cap of Alembic Pharmaceuticals is ₹20627.3 Cr As on 28 December, 2024 | 02:13

The P/E ratio of Alembic Pharmaceuticals is 31.9 As on 28 December, 2024 | 02:13

The PB ratio of Alembic Pharmaceuticals is 4.3 As on 28 December, 2024 | 02:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23